Sera Prognostics, Inc. (NASDAQ:SERA) CFO Sells $19,593.86 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CFO Austin Aerts sold 2,431 shares of Sera Prognostics stock in a transaction on Friday, January 10th. The shares were sold at an average price of $8.06, for a total value of $19,593.86. Following the completion of the sale, the chief financial officer now directly owns 283,325 shares of the company’s stock, valued at $2,283,599.50. This trade represents a 0.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Austin Aerts also recently made the following trade(s):

• On Monday, November 11th, Austin Aerts sold 7,179 shares of Sera Prognostics stock. The shares were sold at an average price of $7.32, for a total value of $52,550.28.

Sera Prognostics Stock Performance

NASDAQ:SERA traded up $0.04 on Tuesday, hitting $6.37. 134,610 shares of the stock were exchanged, compared to its average volume of 143,614. The stock has a market capitalization of $215.13 million, a price-to-earnings ratio of -6.43 and a beta of 0.86. Sera Prognostics, Inc. has a 52 week low of $4.98 and a 52 week high of $12.35. The company’s 50-day moving average price is $7.44 and its 200 day moving average price is $7.31.

Sera Prognostics (NASDAQ:SERA) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.09 million. During the same period last year, the business posted ($0.23) earnings per share. As a group, equities research analysts predict that Sera Prognostics, Inc. will post -0.96 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Barclays PLC increased its holdings in Sera Prognostics by 321.6% in the third quarter. Barclays PLC now owns 39,450 shares of the company’s stock valued at $308,000 after purchasing an additional 30,093 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Sera Prognostics by 100.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 150,708 shares of the company’s stock worth $892,000 after buying an additional 75,441 shares during the period. Geode Capital Management LLC increased its stake in shares of Sera Prognostics by 8.9% in the 3rd quarter. Geode Capital Management LLC now owns 586,837 shares of the company’s stock valued at $4,578,000 after acquiring an additional 47,969 shares during the last quarter. Quest Partners LLC raised its position in shares of Sera Prognostics by 533.5% in the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock valued at $50,000 after acquiring an additional 5,415 shares during the period. Finally, State Street Corp boosted its stake in Sera Prognostics by 8.8% during the 3rd quarter. State Street Corp now owns 425,093 shares of the company’s stock worth $3,316,000 after acquiring an additional 34,479 shares during the last quarter. Institutional investors and hedge funds own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.